Centessa Pharmaceuticals (CNTA) Current Assets (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Current Assets data on file, last reported at $348.7 million in Q1 2026.

• Quarterly Current Assets changed 0.28% year-over-year to $348.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $348.7 million (changed 0.28% YoY) and the FY2025 annual result came in at $367.9 million, down 31.42% from the prior year.
• Current Assets slipped to $348.7 million in Q1 2026 per CNTA's latest filing, from $367.9 million in the prior quarter.
• Across five years, Current Assets topped out at $581.2 million in Q1 2022 and bottomed at $284.5 million in Q1 2024.
• The 5-year median for Current Assets is $355.5 million (2024), against an average of $400.9 million.
• The widest annual swing landed in 2024, when Current Assets jumped 70.96%; it then slumped 45.87% in 2025.
• Tracing CNTA's Current Assets over 5 years: stood at $437.7 million in 2022, then dropped by 28.02% to $315.1 million in 2023, then soared by 70.24% to $536.4 million in 2024, then slumped by 31.42% to $367.9 million in 2025, then slipped by 5.22% to $348.7 million in 2026.
• Per Business Quant, the three latest CNTA Current Assets figures stand at $348.7 million (Q1 2026), $367.9 million (Q4 2025), and $307.7 million (Q3 2025).

Peer Comparison